Previsioni
| Acquista |
6 |
| Mantieni |
2 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Lifeward shareholders approve partnership with Oramed and potential capital injection
Lifeward has approved the issuance of common shares as part of a strategic partnership with Oramed, potentially giving the company access to up to about $47 million from Oramed and an additional investor. The financing includes equity, convertible bonds, milestone payments and warrants. Oramed will manage and fund the clinical development program for the POD technology, which aims to enable oral delivery of biopharmaceuticals, while Lifeward will focus on its medical technology business. Lifeward shares jumped more than 10% after the announcement but remain down around 65% year-to-date; completion of the transaction is still subject to customary conditions. » Altro su de.investing.com
Oramed receives $18 million from Scilex and announces cash dividend
Oramed has received a payment of $18 million from Scilex, fulfilling all obligations under an option agreement and raising the total return on the original $99.5 million investment to $118 million. Oramed also retains a $27 million promissory note, a $12 million convertible note (conversion price $36 per share), warrants and a nine‑year royalty/license interest in Scilex products. The board approved a cash dividend of $0.25 per share (ex‑date January 16, 2026; payment January 26, 2026), to be financed from surplus funds; the share price then rose by about 6.2%. » Altro su de.investing.com
Oramed Pharmaceuticals: Leonard Sank steps down from director post after 18 years
Leonard Sank has announced he will resign his mandate on the supervisory board of Oramed Pharmaceuticals effective January 1, 2026. The company emphasizes that his resignation is not due to disagreements over management, policies, or practices. Sank served 18 years as a director. » Altro su de.investing.com
Oramed completes repurchase of Scilex warrants for $28.5m
Oramed received a total of $28.5 million from Scilex for the repurchase of warrants to acquire 6,500,000 Scilex common shares (two tranches: 3,370,000 shares for $14 million and 3,130,000 shares for $13 million, plus $1.5 million in option fees). The warrants had an exercise price of $0.01 and were repurchased under an agreement disclosed in July. In addition, Oramed repurchased 1,155,367 of its own common shares for about $2.58 million and ended a joint venture with HTIT/Technowl; the company now plans to continue its oral insulin program independently and to initiate a new U.S. study. » Altro su de.investing.com
Oramed buys back HTIT shares and ends joint venture
Oramed repurchased 1,155,367 common shares of Hefei Tianhui Biotech (HTIT) at $2.23 each (about $2.58 million) and had the shares cancelled. The company terminated the joint-venture agreement with HTIT and Technowl after HTIT failed to meet closing conditions. Oramed released preliminary, unaudited financials as of September 30, 2025, and launched a new U.S. study for its oral insulin program with 60 identified high responders. It also completed the first tranche of an option repurchase agreement with Scilex (3,130,000 shares for $13 million) and increased the number of authorized shares under its stock option plan by 2,000,000 to 9,500,000. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheNel 2026, Oramed Pharmaceuticals ha già distribuito 0,21 € di dividendi. L'ultimo pagamento è avvenuto a gennaio.
Dati finanziari
Nell'ultimo trimestre, Oramed Pharmaceuticals ha registrato ricavi pari a 0 € e un utile netto di 16,25 Mln €
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 0 | - |
| Utile lordo | 0 | 100,00% |
| Utile netto | 16,25 Mln | 60,59% |
| EBITDA | 24,99 Mln | 50,69% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 141,48 Mln € |
Numero di azioni | 43,49 Mln |
Massimo/minimo a 52 settimane | 4,99 € - 2,30 € |
Rendimento da dividendo | 6,00% |
Dividendi TTM | 0,21 € |
Beta | 1,28 |
Rapporto P/E | 1,02 |
Rapporto PEG | 0,00 |
Rapporto P/B | 0,44 |
Rapporto P/S | 0,00 |
Profilo aziendale
Oramed Pharmaceuticals Inc. si occupa della ricerca e dello sviluppo di soluzioni farmaceutiche per il trattamento del diabete e per l'uso di capsule o pillole ingeribili per via orale destinate alla somministrazione di polipeptidi. Il suo prodotto di punta brevettato è l'ORMD-0801, una capsula di insulina ingeribile per via orale, che ha completato le sperimentazioni cliniche di fase II per il trattamento di persone affette da diabete. L'azienda sta inoltre sviluppando l'ORMD-0901, una capsula orale di peptide-1 simile al glucagone che ha completato le sperimentazioni cliniche di fase I per il trattamento del diabete di tipo 2; e un trattamento per la perdita di peso sotto forma di capsula orale di leptina. In precedenza la società era nota come Integrated Security Technologies, Inc. e ha cambiato denominazione in Oramed Pharmaceuticals Inc. nell'aprile 2006. Oramed Pharmaceuticals Inc. è stata fondata nel 2002 ed ha sede a New York, New York.
| Nome | Oramed Pharmaceuticals |
| CEO | Nadav Kidron |
| Sede centrale | New York City,
ny Stati Uniti |
| Sito web | |
| Settore | Materiali |
| Industria | Prodotti chimici |
| Quotazione in borsa | 01/05/2007 |
| Dipendenti | 13 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
Tlv | ORMP.TA |
NASDAQ | ORMP |
Frankfurt | OJU1.F |
Düsseldorf | OJU1.DU |
München | OJU1.MU |